rovatirelin (KPS-0373) / Shionogi, Kissei - LARVOL DELTA

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration (clinicaltrials.gov) - P3 | N=142 | Active, not recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders

Confirmatory Study 3 of KPS-0373 in Patients With Spinocerebellar Degeneration (clinicaltrials.gov) - P3 | N=142 | Recruiting | Sponsor: Kissei Pharmaceutical Co., Ltd.

New P3 trial • CNS Disorders

A Systematic Literature Review on the Efficacy of Pharmacological Interventions in Ataxia (ISPOR-EU 2024) - "Across these, idebenone and riluzole (2 studies each) were the most commonly assessed interventions, followed by one study each for amantadine hydrochloride, deferiprone, luvadaxistat, omaveloxolone, rovatirelin, and troriluzole. Limited therapeutic options are available for ataxia, often focusing on symptomatic management rather than addressing the underlying cause. This SLR underscores a notable gap in treatments that directly target ataxia and highlights the potential pharmacological treatments in treating ataxia or slowing its progression."

Clinical • Review • Ataxia • CNS Disorders • Friedreich ataxia • Movement Disorders

Rovatirelin ameliorates motor dysfunction in the cytosine arabinoside-induced rat model of spinocerebellar degeneration via acetylcholine and dopamine neurotransmission. (PubMed, Clin Exp Pharmacol Physiol) - "In conclusion, oral administration of rovatirelin ameliorates motor dysfunction in rats with Ara-C-induced ataxia, owing to its ACh-increasing effects in the mPFC and DA-increasing effects in the dorsal striatum and NAc. Furthermore, the effects of rovatirelin were more potent than those of taltirelin."

Journal • Preclinical • Ataxia • CNS Disorders • Movement Disorders